Our results revealed densely packed DCX-positive cells in the entire extent of the subventricular zone from where cells migrated along the rostral migratory stream to the olfactory bulb. In the olfactory bulb, DCX-expressing cells were primarily present in the granular Compound C mw cell layer with radially orientated dendrites and in
the glomerular layer representing periglomerular cells. In the hippocampus, DCX-positive cells were identified in the subgranular and granular layers of the dentate gyrus and strongly labelled DCX-positive processes, presumably dendrites and axons of the newly generated granular cells, were observed in the CA3 regions. In addition, DCX immunoreactive cells were present in the olfactory tubercle, the piriform cortex and the endopiriform nucleus. While DCX-positive fibres have been previously observed in the anterior commissure of the hedgehog and mole, we were able to demonstrate
the presence Selleckchem GANT61 of DCX-positive cells presumably migrating across the anterior commissure. Taken together, the giant otter shrew reveals patterns of neurogenesis similar to that seen in other mammals; however, the appearance of possible neuronal precursor cells in the anterior commissure is a novel observation. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.”
“The HIV pandemic represents a major source of neurological morbidity worldwide. Emerging data from diverse populations indicate that HIV leads to significant neurocognitive impairments that reduce individuals’ ability to contribute to the well being of their families and society. HIV affects vulnerable populations with many comorbidities, but the virus contributes to neurocognitive impairment independent of these conditions. The neuropathological
substrate of HIV neurocognitive disorders is damage to synapses Epothilone B (EPO906, Patupilone) and dendrites, without major neuronal loss. This suggests the potential for substantial reversibility if synaptodendritic function can be restored. In the developed world, combination antiretroviral therapy (CART) leads to improved neurocognitive function as well as morbidity and mortality in HIV. CART is being used in increasing numbers of individuals in resource limited settings. New cases of severe dementia are now rare in populations where effective CART has been deployed. While some degree of neurocognitive improvement with CART is almost universal, many individuals do not achieve full restoration of their premorbid neurocognitive status, and milder degrees of impairment remain quite prevalent. Optimizing neurocognitive recovery is likely to require the development of better CNS penetrating antiretroviral regimens and the use of neuroprotective agents. (C) 2009 Elsevier Ltd. All rights reserved.
No related posts.